Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 179

1.

B-cell precursor acute lymphoblastic leukemia and stromal cells communicate through Galectin-3.

Fei F, Joo EJ, Tarighat SS, Schiffer I, Paz H, Fabbri M, Abdel-Azim H, Groffen J, Heisterkamp N.

Oncotarget. 2015 Mar 30. [Epub ahead of print]

2.

Cytotoxicity of CD56-positive lymphocytes against autologous B-cell precursor acute lymphoblastic leukemia cells.

Fei F, Lim M, George AA, Kirzner J, Lee D, Seeger R, Groffen J, Abdel-Azim H, Heisterkamp N.

Leukemia. 2015 Apr;29(4):788-97. doi: 10.1038/leu.2014.246. Epub 2014 Aug 19.

PMID:
25134458
3.

Effector-mediated eradication of precursor B acute lymphoblastic leukemia with a novel Fc-engineered monoclonal antibody targeting the BAFF-R.

Parameswaran R, Lim M, Fei F, Abdel-Azim H, Arutyunyan A, Schiffer I, McLaughlin ME, Gram H, Huet H, Groffen J, Heisterkamp N.

Mol Cancer Ther. 2014 Jun;13(6):1567-77. doi: 10.1158/1535-7163.MCT-13-1023. Epub 2014 May 13.

PMID:
24825858
4.

Abr, a negative regulator of Rac, attenuates cockroach allergen-induced asthma in a mouse model.

Gong D, Fei F, Lim M, Yu M, Groffen J, Heisterkamp N.

J Immunol. 2013 Nov 1;191(9):4514-20. doi: 10.4049/jimmunol.1202603. Epub 2013 Sep 20.

5.

Galectin-3 in pre-B acute lymphoblastic leukemia.

Fei F, Abdel-Azim H, Lim M, Arutyunyan A, von Itzstein M, Groffen J, Heisterkamp N.

Leukemia. 2013 Dec;27(12):2385-8. doi: 10.1038/leu.2013.175. Epub 2013 Jun 13. No abstract available.

6.

O-acetylated N-acetylneuraminic acid as a novel target for therapy in human pre-B acute lymphoblastic leukemia.

Parameswaran R, Lim M, Arutyunyan A, Abdel-Azim H, Hurtz C, Lau K, Müschen M, Yu RK, von Itzstein M, Heisterkamp N, Groffen J.

J Exp Med. 2013 Apr 8;210(4):805-19. doi: 10.1084/jem.20121482. Epub 2013 Mar 11.

7.

Adipose tissue attracts and protects acute lymphoblastic leukemia cells from chemotherapy.

Pramanik R, Sheng X, Ichihara B, Heisterkamp N, Mittelman SD.

Leuk Res. 2013 May;37(5):503-9. doi: 10.1016/j.leukres.2012.12.013. Epub 2013 Jan 17.

8.

Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy.

Hsieh YT, Gang EJ, Geng H, Park E, Huantes S, Chudziak D, Dauber K, Schaefer P, Scharman C, Shimada H, Shojaee S, Klemm L, Parameswaran R, Loh M, Kang ES, Koo HH, Hofmann WK, Andrade J, Crooks GM, Willman CL, Müschen M, Papayannopoulou T, Heisterkamp N, Bönig H, Kim YM.

Blood. 2013 Mar 7;121(10):1814-8. doi: 10.1182/blood-2012-01-406272. Epub 2013 Jan 14.

9.

Lack of bcr and abr promotes hypoxia-induced pulmonary hypertension in mice.

Yu M, Gong D, Lim M, Arutyunyan A, Groffen J, Heisterkamp N.

PLoS One. 2012;7(11):e49756. doi: 10.1371/journal.pone.0049756. Epub 2012 Nov 12.

10.

Environment-mediated drug resistance in Bcr/Abl-positive acute lymphoblastic leukemia.

Feldhahn N, Arutyunyan A, Stoddart S, Zhang B, Schmidhuber S, Yi SJ, Kim YM, Groffen J, Heisterkamp N.

Oncoimmunology. 2012 Aug 1;1(5):618-629.

11.

Expression of cassini, a murine gamma-satellite sequence conserved in evolution, is regulated in normal and malignant hematopoietic cells.

Arutyunyan A, Stoddart S, Yi SJ, Fei F, Lim M, Groffen P, Feldhahn N, Groffen J, Heisterkamp N.

BMC Genomics. 2012 Aug 23;13:418. doi: 10.1186/1471-2164-13-418.

12.

Regulation of dendritic arborization by BCR Rac1 GTPase-activating protein, a substrate of PTPRT.

Park AR, Oh D, Lim SH, Choi J, Moon J, Yu DY, Park SG, Heisterkamp N, Kim E, Myung PK, Lee JR.

J Cell Sci. 2012 Oct 1;125(Pt 19):4518-31. doi: 10.1242/jcs.105502. Epub 2012 Jul 5.

13.

Treatment of human pre-B acute lymphoblastic leukemia with the Aurora kinase inhibitor PHA-739358 (Danusertib).

Fei F, Lim M, Schmidhuber S, Moll J, Groffen J, Heisterkamp N.

Mol Cancer. 2012 Jun 21;11:42. doi: 10.1186/1476-4598-11-42.

14.

TGFβ signaling plays a critical role in promoting alternative macrophage activation.

Gong D, Shi W, Yi SJ, Chen H, Groffen J, Heisterkamp N.

BMC Immunol. 2012 Jun 15;13:31. doi: 10.1186/1471-2172-13-31.

15.

Treatment of acute lymphoblastic leukemia with an rGel/BLyS fusion toxin.

Parameswaran R, Yu M, Lyu MA, Lim M, Rosenblum MG, Groffen J, Heisterkamp N.

Leukemia. 2012 Aug;26(8):1786-96. doi: 10.1038/leu.2012.54. Epub 2012 Feb 29.

16.

Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia.

Park E, Gang EJ, Hsieh YT, Schaefer P, Chae S, Klemm L, Huantes S, Loh M, Conway EM, Kang ES, Hoe Koo H, Hofmann WK, Heisterkamp N, Pelus L, Keerthivasan G, Crispino J, Kahn M, Müschen M, Kim YM.

Blood. 2011 Aug 25;118(8):2191-9. doi: 10.1182/blood-2011-04-351239. Epub 2011 Jun 28.

17.

BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition.

Duy C, Hurtz C, Shojaee S, Cerchietti L, Geng H, Swaminathan S, Klemm L, Kweon SM, Nahar R, Braig M, Park E, Kim YM, Hofmann WK, Herzog S, Jumaa H, Koeffler HP, Yu JJ, Heisterkamp N, Graeber TG, Wu H, Ye BH, Melnick A, Müschen M.

Nature. 2011 May 19;473(7347):384-8. doi: 10.1038/nature09883.

18.

Philadelphia Chromosome Symposium: commemoration of the 50th anniversary of the discovery of the Ph chromosome.

Chandra HS, Heisterkamp NC, Hungerford A, Morrissette JJ, Nowell PC, Rowley JD, Testa JR.

Cancer Genet. 2011 Apr;204(4):171-9. doi: 10.1016/j.cancergen.2011.03.002.

19.

Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist.

Parameswaran R, Yu M, Lim M, Groffen J, Heisterkamp N.

Leukemia. 2011 Aug;25(8):1314-23. doi: 10.1038/leu.2011.76. Epub 2011 Apr 12.

20.

AMD3100 sensitizes acute lymphoblastic leukemia cells to chemotherapy in vivo.

Yu M, Gang EJ, Parameswaran R, Stoddart S, Fei F, Schmidhuber S, Park E, Hsieh YT, Yang AS, Groffen J, Heisterkamp N, Kim YM.

Blood Cancer J. 2011 Apr;1(4):e14. doi: 10.1038/bcj.2011.13. Epub 2011 Apr 1. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk